| Name | Title | Contact Details |
|---|
Based in San Diego and founded in 2013, Omniome is a biotechnology company developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome`s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. We are a quality-focused, start-up environment where development thrives. Our culture is inspiring, fun and consists of a talented team of individuals who propose innovative ideas keeping collaboration a top priority.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1).
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
Notable Labs is a translationally focused drug development company that uses a clinically validated, automated compound sensitivity platform to identify and advance novel therapeutic candidates to dramatically reduce the cost and time of the traditional drug development process.